发明名称 A PEPTIDE LIGAND TO IMPAIR CANCER CELL MIGRATION
摘要 Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a 13 peptide fragments were identified and investigated for their ability to mimic the effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumourigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumour cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formylation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumour cell motility. The novel formyl-Met-Asp-Gly-Cys-Glu-Leu peptide ligand can serve as a lead substance for anti-metastatic treatment in the «50% of human breast cancers where the endogenous expression of Wnt-5a is reduced.
申请公布号 CA2609221(C) 申请公布日期 2014.07.08
申请号 CA20062609221 申请日期 2006.05.30
申请人 FORSKARPATENT I SYD AB 发明人 ANDERSSON, TOMMY
分类号 C07K14/475;A61K38/18;A61P35/04 主分类号 C07K14/475
代理机构 代理人
主权项
地址